IL-10 production in multiple sclerosis patients, SLE patients and healthy controls: preliminary findings.
IL-10 is a cytokine with suppressive effects on (auto) antigen presentation and T-cell-mediated immune reactions, but is also capable of stimulating polyclonal IgG synthesis. Recent evidence suggests its involvement in multiple sclerosis (MS) and systemic lupus erythematosus (SLE). We assessed PBMNC IL-10 release in MS and SLE patients before and after in vivo prednisone or methylprednisolone treatment. The SLE patients showed a high level of IL-10 release by unstimulated PBMNCs, whereas the PHA-stimulated PBMNCs from MS patients produced large amounts of the cytokine.
Gelati
M
M
Istituto Nazionale Neurologico C. Besta, Milano, Italy.
Lamperti
E
E
Dufour
A
A
Corsini
E
E
Venegoni
E
E
Milanese
C
C
Nespolo
A
A
Salmaggi
A
A
D000328:Adult; D000368:Aged; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D016753:Interleukin-10 / Q000096:biosynthesis*; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000378:metabolism*; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy / Q000378:metabolism*; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy / Q000378:metabolism*; D011241:Prednisone / Q000627:therapeutic use
D016753:Interleukin-10; D011241:Prednisone; D008775:Methylprednisolone